SEC Form 4 · accession 0001553878-15-000006
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marsha Fanucci
Director
Period of report
Feb 25, 2015
Accepted (ET)
Feb 27, 2015 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 25, 2015 | S | 3,654 | $104.8329 | D | 6,346 | D | |
| Common StockF3 | Feb 25, 2015 | S | 2,621 | $105.6564 | D | 3,725 | D | |
| Common StockF4 | Feb 25, 2015 | S | 3,025 | $106.7167 | D | 700 | D | |
| Common StockF5 | Feb 25, 2015 | S | 700 | $107.3571 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2014.
- F2Sale prices ranged from $104.14 to $105.13.
- F3Sale prices ranged from $105.19 to $106.13.
- F4Sale prices ranged from $106.20 to $107.16.
- F5Sale prices ranged from $107.20 to $107.59.